Mobile

The ARRIVE Study (Aspirin to Reduce Risk of Initial Vascular Events) - A Randomized, Double-Blind, Placebo Controlled, Multicenter, Parallel Group Study to Assess the Efficacy (Reduction of Cardiovasc...

Update Il y a 4 ans
Reference: EUCTR2006-003622-29

The ARRIVE Study (Aspirin to Reduce Risk of Initial Vascular Events) - A Randomized, Double-Blind, Placebo Controlled, Multicenter, Parallel Group Study to Assess the Efficacy (Reduction of Cardiovascular Disease Events) and Safety of 100 mg Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To evaluate the clinical effect of a 100 mg/day enteric coated aspirin vs placebo in the reduction of CVD events in patients at moderate risk of CHD events (approx 10 - 20% 10 year-risk). This corresponds to a patient population mean 10-year CVD risk of approx 30% based on the underlying assumption at study start.

Inclusion criteria

  • Patients at moderate risk of CHD events (10-20% 10-year CHD risk;
  • approximately 30% 10-year risk of CVD events based on the underlying
  • assumption at study start)

Links